Hydroxyurea treatment of sickle cell anemia in hospital-based practices

Robert P. Ferguson, Anuradha Arun, Chris Carter, Stanley D. Walker, Oswaldo Castro

Research output: Contribution to journalArticle

Abstract

In a published randomized clinical trial, hydroxyurea (HU) Improved clinical outcomes In patients with sickle cell anemia (SCA). The mean treatment duration of that trial was 21 months. Here we attempt to determine whether the benefits associated with HU therapy of SCA have led also to successful patient acceptance of HU treatment in community practices, and whether successful clinical outcomes persist beyond 2 years. This is an observational retrospective chart study of the computerized medical records of 60 men and women with SCA who had HU treatment for at least 3 months and who were treated at teaching hospital subspecialty clinics in Baltimore, Maryland, and Washington, D.C. Thirty had remained on therapy for at least 24 months. Admissions declined in this group by 30% (P = 0.04). Declines were seen also in transfusion requirements (-58%, P = 0.07). In 17 of these 30 patients, at least 48 months of follow-up records were available. Fourteen of these remained on therapy the entire period, with similar and sustained reductions in admissions and transfusions. We conclude that hydroxyurea therapy of SCA applied in community settings leads to declining admissions and transfusion rates in many individuals for 4 years or more.

Original languageEnglish (US)
Pages (from-to)326-328
Number of pages3
JournalAmerican Journal of Hematology
Volume70
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Therapeutics
Computerized Medical Records Systems
Baltimore
Teaching Hospitals
Randomized Controlled Trials
Retrospective Studies

Keywords

  • Hospital practice
  • Hydroxyurea
  • Sickle cell anemia

ASJC Scopus subject areas

  • Hematology

Cite this

Ferguson, R. P., Arun, A., Carter, C., Walker, S. D., & Castro, O. (2002). Hydroxyurea treatment of sickle cell anemia in hospital-based practices. American Journal of Hematology, 70(4), 326-328. https://doi.org/10.1002/ajh.10184

Hydroxyurea treatment of sickle cell anemia in hospital-based practices. / Ferguson, Robert P.; Arun, Anuradha; Carter, Chris; Walker, Stanley D.; Castro, Oswaldo.

In: American Journal of Hematology, Vol. 70, No. 4, 2002, p. 326-328.

Research output: Contribution to journalArticle

Ferguson, RP, Arun, A, Carter, C, Walker, SD & Castro, O 2002, 'Hydroxyurea treatment of sickle cell anemia in hospital-based practices', American Journal of Hematology, vol. 70, no. 4, pp. 326-328. https://doi.org/10.1002/ajh.10184
Ferguson, Robert P. ; Arun, Anuradha ; Carter, Chris ; Walker, Stanley D. ; Castro, Oswaldo. / Hydroxyurea treatment of sickle cell anemia in hospital-based practices. In: American Journal of Hematology. 2002 ; Vol. 70, No. 4. pp. 326-328.
@article{a93f64ad8a674724856f3602d5cef8f7,
title = "Hydroxyurea treatment of sickle cell anemia in hospital-based practices",
abstract = "In a published randomized clinical trial, hydroxyurea (HU) Improved clinical outcomes In patients with sickle cell anemia (SCA). The mean treatment duration of that trial was 21 months. Here we attempt to determine whether the benefits associated with HU therapy of SCA have led also to successful patient acceptance of HU treatment in community practices, and whether successful clinical outcomes persist beyond 2 years. This is an observational retrospective chart study of the computerized medical records of 60 men and women with SCA who had HU treatment for at least 3 months and who were treated at teaching hospital subspecialty clinics in Baltimore, Maryland, and Washington, D.C. Thirty had remained on therapy for at least 24 months. Admissions declined in this group by 30{\%} (P = 0.04). Declines were seen also in transfusion requirements (-58{\%}, P = 0.07). In 17 of these 30 patients, at least 48 months of follow-up records were available. Fourteen of these remained on therapy the entire period, with similar and sustained reductions in admissions and transfusions. We conclude that hydroxyurea therapy of SCA applied in community settings leads to declining admissions and transfusion rates in many individuals for 4 years or more.",
keywords = "Hospital practice, Hydroxyurea, Sickle cell anemia",
author = "Ferguson, {Robert P.} and Anuradha Arun and Chris Carter and Walker, {Stanley D.} and Oswaldo Castro",
year = "2002",
doi = "10.1002/ajh.10184",
language = "English (US)",
volume = "70",
pages = "326--328",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Hydroxyurea treatment of sickle cell anemia in hospital-based practices

AU - Ferguson, Robert P.

AU - Arun, Anuradha

AU - Carter, Chris

AU - Walker, Stanley D.

AU - Castro, Oswaldo

PY - 2002

Y1 - 2002

N2 - In a published randomized clinical trial, hydroxyurea (HU) Improved clinical outcomes In patients with sickle cell anemia (SCA). The mean treatment duration of that trial was 21 months. Here we attempt to determine whether the benefits associated with HU therapy of SCA have led also to successful patient acceptance of HU treatment in community practices, and whether successful clinical outcomes persist beyond 2 years. This is an observational retrospective chart study of the computerized medical records of 60 men and women with SCA who had HU treatment for at least 3 months and who were treated at teaching hospital subspecialty clinics in Baltimore, Maryland, and Washington, D.C. Thirty had remained on therapy for at least 24 months. Admissions declined in this group by 30% (P = 0.04). Declines were seen also in transfusion requirements (-58%, P = 0.07). In 17 of these 30 patients, at least 48 months of follow-up records were available. Fourteen of these remained on therapy the entire period, with similar and sustained reductions in admissions and transfusions. We conclude that hydroxyurea therapy of SCA applied in community settings leads to declining admissions and transfusion rates in many individuals for 4 years or more.

AB - In a published randomized clinical trial, hydroxyurea (HU) Improved clinical outcomes In patients with sickle cell anemia (SCA). The mean treatment duration of that trial was 21 months. Here we attempt to determine whether the benefits associated with HU therapy of SCA have led also to successful patient acceptance of HU treatment in community practices, and whether successful clinical outcomes persist beyond 2 years. This is an observational retrospective chart study of the computerized medical records of 60 men and women with SCA who had HU treatment for at least 3 months and who were treated at teaching hospital subspecialty clinics in Baltimore, Maryland, and Washington, D.C. Thirty had remained on therapy for at least 24 months. Admissions declined in this group by 30% (P = 0.04). Declines were seen also in transfusion requirements (-58%, P = 0.07). In 17 of these 30 patients, at least 48 months of follow-up records were available. Fourteen of these remained on therapy the entire period, with similar and sustained reductions in admissions and transfusions. We conclude that hydroxyurea therapy of SCA applied in community settings leads to declining admissions and transfusion rates in many individuals for 4 years or more.

KW - Hospital practice

KW - Hydroxyurea

KW - Sickle cell anemia

UR - http://www.scopus.com/inward/record.url?scp=0036330307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036330307&partnerID=8YFLogxK

U2 - 10.1002/ajh.10184

DO - 10.1002/ajh.10184

M3 - Article

C2 - 12214583

AN - SCOPUS:0036330307

VL - 70

SP - 326

EP - 328

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -